研究

Takaya H, Nakai H, Sakai K, Nishio K, Murakami K, Mandai M, Matsumura N.

Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course

Takeda M, Sakai K, Hayashi H, Tanaka K, Haratani K, Takahama T, Kato R, Yonesaka K, Nishio K, Nakagawa K.

Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs

Iwama E, Sakai K, Hidaka N, Inoue K, Fujii A, Nakagaki N, Ota K, Toyozawa R, Azuma K, Nakatomi K, Harada T, Hisasue J, Sakata S, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.

Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors

Komeda Y, Sakurai T, Sakai K, Morita Y, Hashimoto A, Nagai T, Hagiwara S, Matsumura I, Nishio K, Kudo M.

Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report.

Ohara S, Suda K, Sakai K, Nishino M, Chiba M, Shimoji M, Takemoto T, Fujino T, Koga T, Hamada A, Soh J, Nishio K, Mitsudomi T.

Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study

Noguchi T, Iwahashi N, Sakai K, Matsuda K, Matsukawa H, Toujima S, Nishio K, Ino K.

Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact

Sakurai T, Nishiyama H, Sakai K, De Velasco MA, Nagai T, Komeda Y, Kashida H, Okada A, Kawai I, Nishio K, Ogata H, Kudo M.

Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis.

Hayashi H, Takiguchi Y, Minami H, Akiyoshi K, Segawa Y, Ueda H, Iwamoto Y, Kondoh C, Matsumoto K, Takahashi S, Yasui H, Sawa T, Onozawa Y, Chiba Y, Togashi Y, Fujita Y, Sakai K, Tomida S, Nishio K, Nakagawa K.

Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.

Honobe A, Sakai K, Togashi Y, Ohnuma T, Kawamura T, Nishio K, Inozume T.

Heterogeneity in congenital melanocytic nevi contributes to multicentric melanomagenesis.

Kondo T, Kanai M, Matsubara J, Quy PN, Fukuyama K, Yamamoto Y, Yamada T, Nishigaki M, Minamiguchi S, Takeda M, Nishio K, Matsumoto S, Muto M.

BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer.

Nishida N, Sakai K, Morita M, Aoki T, Takita M, Hagiwara S, Komeda Y, Takenaka M, Minami Y, Ida H, Ueshima K, Nishio K, Kudo M.

Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1

Yatabe Y, Sunami K, Goto K, Nishio K, Aragane N, Ikeda S, Inoue A, Kinoshita I, Kimura H, Sakamoto T, Satouchi M, Shimizu J, Tsuta K, Toyooka S, Nishino K, Hatanaka Y, Matsumoto S, Mikubo M, Yokose T, Dosaka-Akita H.

Multiplex Gene-panel Testing for Lung Cancer Patients.

Kawanaka Y, Kawakami H, Shimizu S, Yoshida T, Hayashi H, Nishio K, Satou T, Nakagawa K.

A Case of Pulmonary Tumor Thrombotic Microangiopathy Suggested by the Presence of Tumor Cells in Peripheral Blood.

Suda K, Murakami I, Obata K, Sakai K, Fujino T, Koga T, Ohara S, Hamada A, Soh J, Nishio K, Mitsudomi T.

Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer.

Omura S, Sato F, Park AM, Fujita M, Khadka S, Nakamura Y, Katsuki A, Nishio K, Gavins FNE, Tsunoda I.

Bioinformatics Analysis of Gut Microbiota and CNS Transcriptome in Virus-Induced Acute Myelitis and Chronic Inflammatory Demyelination; Potential Association of Distinct Bacteria with CNS IgA upregulation

Sakai H, Takeda M, Sakai K, Nishio K, Nakagawa K.

Long-term response to ipilimumab after nivolumab failure in a case of anorectal melanoma with an intermediate tumor mutation burden and negative for PD-L1 expression.

Shimizu T, Nishio K, Sakai K, Okamoto I, Okamoto K, Takeda M, Morishita M, Nakagawa K.

Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer

Noguchi T, Sakai K, Iwahashi N, Matsuda K, Matsukawa H, Yahata T, Toujima S, Nishio K, Ino K.

Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer.

Takahama T, Azuma K, Shimokawa M, Takeda M, Ishii H, Kato T, Saito H, Daga H, Tsuboguchi Y, Okamoto I, Otsubo K, Akamatsu H, Teraoka S, Takahashi T, Ono A, Ohira T, Yokoyama T, Sakai K, Yamamoto N, Nishio K, Nakagawa K.

Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.

Ishii H, Azuma K, Sakai K, Naito Y, Matsuo N, Tokito T, Yamada K, Hoshino T, Nishio K.

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib.

Haratani K, Yonesaka K, Takamura S, Maenishi O, Kato R, Takegawa N, Kawakami H, Tanaka K, Hayashi H, Takeda M, Maeda N, Kagari T, Hirotani K, Tsurutani J, Nishio K, Doi K, Miyazawa M, Nakagawa K.

U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.